Skip to content
value.today

AS Grindeks: peers

Change the peers

AS Grindeks beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

AS Grindeks, As Olainfarm, Egetis Therapeutics AB (publ), Pihlajalinna Oyj, Photocure ASA, Tiziana Life Sciences Ltd, Adaptimmune Therapeutics, Xspray Pharma AB (publ): the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

AS Grindeks, As Olainfarm, Egetis Therapeutics AB (publ), Pihlajalinna Oyj, Photocure ASA, Tiziana Life Sciences Ltd, Adaptimmune Therapeutics, Xspray Pharma AB (publ) side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureAS Grindeksbase
GRD1R.RG · 🇱🇻 LV
Percentile in Healthcare
Percentile in Latvia
As Olainfarm
UU4.F · 🇱🇻 LV
Percentile in Healthcare
Percentile in Latvia
Egetis Therapeutics AB (publ)
EGTX.ST · 🇸🇪 SE
Percentile in Healthcare
Percentile in Sweden
Pihlajalinna Oyj
PIHLIS.HE · 🇫🇮 FI
Percentile in Healthcare
Percentile in Finland
Photocure ASA
PHO.OL · 🇳🇴 NO
Percentile in Healthcare
Percentile in Norway
Tiziana Life Sciences Ltd
TLSA · 🇬🇧 GB
Percentile in Healthcare
Percentile in UK
Adaptimmune Therapeutics
ADAP · 🇬🇧 GB
Percentile in Healthcare
Percentile in UK
Xspray Pharma AB (publ)
XSPRAY.ST · 🇸🇪 SE
Percentile in Healthcare
Percentile in Sweden
Group median
Size
Market cap (Better neither way: ranked highest first)$158 Mlast known, Jan 1, 2021 · Market dataLast known value: no current one5th of 8$124 Mlast known, Jan 1, 2021 · Market dataLast known value: no current one7th of 8$164 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one4th of 8$174 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one2nd of 8$172 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8$144 MAug 1, 2026 · Market data6th of 8$200 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one1st of 8$121 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one8th of 8$161 M8 ranked
Revenue (Better neither way: ranked highest first)——$119 MFY2022 · Wikidata3rd of 6$6 MFY2025 · ESEF5th of 6$735 MFY2025 · ESEF1st of 6$51 MFY2025 · ESEF4th of 6——$178 MFY2024 · SEC2nd of 6$0 MFY2025 · ESEF6th of 6$85 M6 ranked
Net income (Higher is better)——$19 MFY2022 · Wikidata2nd of 7$-35 MFY2025 · ESEF6th of 7$42 MFY2025 · ESEF1st of 7$-0 MFY2025 · ESEF3rd of 7$-12 MFY2024 · SEC4th of 7$-71 MFY2024 · SEC7th of 7$-17 MFY2025 · ESEF5th of 7$-12 M7 ranked
Employees (Better neither way: ranked highest first)——1,0542022 · Profile1st of 2——————3December 31, 2025 · Profile2nd of 2————5292 ranked
Growth
Revenue growth (Higher is better)————————+45.6%FY2025 · ESEF2nd of 483rd97th-3.5%FY2025 · ESEF4th of 419th20th+4.8%FY2025 · ESEF3rd of 437th40th————+195.3%FY2024 · SEC1st of 496th99th————+25.2%4 ranked
Revenue growth, 3 years a year (Higher is better)————————————————————————+207.1%FY2024 · SEConly one with it99th99th————+207.1%—
Earnings per share growth (Higher is better)————————————+45.7%FY2025 · ESEFonly one with it75th81st————————————————+45.7%—
Margins and returns
Gross margin (Higher is better)————————19.8%FY2025 · ESEF3rd of 39th21st————92.1%FY2025 · ESEF2nd of 393rd96th————100.0%FY2024 · SEC1st of 3100th100th————92.1%3 ranked
Operating margin (Higher is better)————————-545.0%FY2025 · ESEF4th of 46th0th8.1%FY2025 · ESEF1st of 470th61st-0.1%FY2025 · ESEF2nd of 457th25th————-38.6%FY2024 · SEC3rd of 435th6th————-19.4%4 ranked
Net margin (Higher is better)————————-549.1%FY2025 · ESEF4th of 44th0th5.8%FY2025 · ESEF1st of 471st66th-0.3%FY2025 · ESEF2nd of 459th28th————-39.8%FY2024 · SEC3rd of 434th7th————-20.0%4 ranked
Free cash flow margin (Higher is better)————————-430.6%FY2025 · ESEF3rd of 38th0th————1.9%FY2025 · ESEF1st of 356th41st————-41.6%FY2024 · SEC2nd of 329th4th————-41.6%3 ranked
Return on equity (Higher is better)————————-85.6%FY2025 · ESEF4th of 629th3rd21.1%FY2025 · ESEF1st of 691st85th-0.3%FY2025 · ESEF2nd of 672nd27th-250.2%FY2024 · SEC5th of 67th1st-275.7%FY2024 · SEC6th of 66th0th-28.6%FY2025 · ESEF3rd of 655th10th-57.1%6 ranked
Valuation
Price to book (Better neither way: ranked highest first)————————————————————36.5×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price——————————
Free cash flow yield (Higher is better)————————————————————-1.1%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price——————————
Financial strength
Debt to equity (Lower is better)————————————————————————4.6×FY2024 · SEConly one with it94th95th————4.6×—
Scorecard
Scorecard (Higher is better)————1 of 5FY2025 · Scorecard3rd of 64 of 5FY2025 · Scorecard1st of 61 of 5FY2025 · Scorecard3rd of 60 of 6FY2024 · Scorecard5th of 69 of 16FY2024 · Scorecard2nd of 60 of 3FY2025 · Scorecard5th of 620% passed6 ranked
Growth checks (Higher is better)————1 of 2FY2025 · Scorecard2nd of 61 of 2FY2025 · Scorecard2nd of 61 of 2FY2025 · Scorecard2nd of 60 of 2FY2024 · Scorecard5th of 65 of 6FY2024 · Scorecard1st of 60 of 1FY2025 · Scorecard5th of 650% passed6 ranked
Profitability checks (Higher is better)————0 of 3FY2025 · Scorecard3rd of 63 of 3FY2025 · Scorecard1st of 60 of 3FY2025 · Scorecard3rd of 60 of 3FY2024 · Scorecard3rd of 62 of 5FY2024 · Scorecard2nd of 60 of 2FY2025 · Scorecard3rd of 60% passed6 ranked
Financial health checks (Higher is better)——————————0 of 1FY2024 · Scorecard2nd of 22 of 4FY2024 · Scorecard1st of 2——25% passed2 ranked
Shareholder returns checks (Higher is better)————————————0 of 1FY2024 · Scorecardonly one with it——0% passed—
Ownership
Held by institutions (Better neither way: ranked highest first)——————————2.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it————2.8%—
Institutions holding (Better neither way: ranked highest first)——————————362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it————36—
Institutional holding, change over the quarter (Better neither way: ranked highest first)——————————-1.0 pp2026-Q2 against 2026-Q1 · 13Fonly one with it————-1.0 pp—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = AS Grindeks: How market caps are worked out; As Olainfarm: How market caps are worked out; Egetis Therapeutics AB (publ): How market caps are worked out; Pihlajalinna Oyj: How market caps are worked out; Photocure ASA: How market caps are worked out; Tiziana Life Sciences Ltd: How market caps are worked out; Adaptimmune Therapeutics: How market caps are worked out; Xspray Pharma AB (publ): How market caps are worked out.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
AS Grindeks———
As Olainfarm———
Egetis Therapeutics AB (publ)-545.0%FY2025
6th percentile in Healthcaremedian -7.7%, 674 companies
0th percentile in Swedenmedian 8.0%, 128 companies
Pihlajalinna Oyj8.1%FY2025
70th percentile in Healthcaremedian -7.7%, 674 companies
61st percentile in Finlandmedian 4.9%, 99 companies
Photocure ASA-0.1%FY2025
57th percentile in Healthcaremedian -7.7%, 674 companies
25th percentile in Norwaymedian 6.0%, 95 companies
Tiziana Life Sciences Ltd———
Adaptimmune Therapeutics-38.6%FY2024
35th percentile in Healthcaremedian -7.7%, 674 companies
6th percentile in UKmedian 8.5%, 313 companies
Xspray Pharma AB (publ)———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$191 M$381 M$572 M$762 M2016201720182019202020212022202320242025Egetis Therapeutics AB (publ) $6 MPihlajalinna Oyj $735 MPhotocure ASA $51 MAdaptimmune Therapeutics $178 MXspray Pharma AB (publ) $0 M

Rank in the group

1st2nd3rd4th5th202220242025As Olainfarm: 1st of 2 in 2022As OlainfarmEgetis Therapeutics AB (publ): 4th of 5 in 2024Egetis Therapeutics AB (publ): 3rd of 4 in 2025Egetis Therapeutics AB (puPihlajalinna Oyj: 1st of 5 in 2024Pihlajalinna Oyj: 1st of 4 in 2025Pihlajalinna OyjPhotocure ASA: 3rd of 5 in 2024Photocure ASA: 2nd of 4 in 2025Photocure ASAAdaptimmune Therapeutics: 2nd of 2 in 2022Adaptimmune Therapeutics: 2nd of 5 in 2024Adaptimmune TherapeuticsXspray Pharma AB (publ): 5th of 5 in 2024Xspray Pharma AB (publ): 4th of 4 in 2025Xspray Pharma AB (publ)
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearAS GrindeksAs OlainfarmEgetis Therapeutics AB (publ)Pihlajalinna OyjPhotocure ASATiziana Life Sciences LtdAdaptimmune TherapeuticsXspray Pharma AB (publ)
2025——$6 MESEF3rd$735 MESEF1st$51 MESEF2nd——$0 MESEF4th
2024——$4 MESEF4th$762 MESEF1st$49 MESEF3rd—$178 MSEC2nd$0 MESEF5th
2023——————$60 MSEC—
2022—$119 MWD1st————$27 MSEC2nd—
2021——————$6 MSEC—
2020——————$4 MSEC—
2019——————$1 MSEC—
2018——————$60 MSEC—
2017——————$38 MSEC—
2016——————$14 MSEC—
2015——————$10 MSEC—

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of AS Grindeks#

Companies of the same industry first, then the same sector, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • As OlainfarmUU4.F · 🇱🇻 Latvia
    Same sector: Healthcare (Pharmaceutical) · Similar size: $124 M market cap against $158 M · Same country: Latvia
    Market cap $124 M (last known, Jan 1, 2021) · revenue $119 M (fiscal 2022)
    68 of 100 (industry or sector 25 + size 28 + country 15)
    In the group
  • Egetis Therapeutics AB (publ)EGTX.ST · 🇸🇪 Sweden
    Same sector: Healthcare (Biotechnology) · Similar size: $164 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $164 M (last known, Jan 5, 2024) · revenue $6 M (year to December 2025)
    67 of 100 (industry or sector 25 + size 30 + country 7 + figures on file 5)
    In the group
  • Pihlajalinna OyjPIHLIS.HE · 🇫🇮 Finland
    Same sector: Healthcare (Medical Care Facilities) · Similar size: $174 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $174 M (last known, Jan 5, 2024) · revenue $735 M (year to December 2025)
    66 of 100 (industry or sector 25 + size 29 + country 7 + figures on file 5)
    In the group
  • Photocure ASAPHO.OL · 🇳🇴 Norway
    Same sector: Healthcare (Pharmaceutical) · Similar size: $172 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $172 M (last known, Jan 5, 2024) · revenue $51 M (year to December 2025)
    66 of 100 (industry or sector 25 + size 29 + country 7 + figures on file 5)
    In the group
  • Tiziana Life Sciences LtdTLSA · 🇬🇧 UK
    Same sector: Healthcare (Biotechnology) · Similar size: $144 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $144 M (Aug 1, 2026)
    66 of 100 (industry or sector 25 + size 29 + country 7 + figures on file 5)
    In the group
  • Adaptimmune TherapeuticsADAP · 🇬🇧 UK
    Same sector: Healthcare (Biotechnology) · Similar size: $200 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $200 M (last known, Jan 5, 2024) · revenue $178 M (year to December 2024)
    66 of 100 (industry or sector 25 + size 29 + country 7 + figures on file 5)
    In the group
  • Xspray Pharma AB (publ)XSPRAY.ST · 🇸🇪 Sweden
    Same sector: Healthcare (Biotechnology) · Similar size: $121 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $121 M (last known, Jan 5, 2024) · revenue $0 M (year to December 2025)
    65 of 100 (industry or sector 25 + size 28 + country 7 + figures on file 5)
    In the group
  • ArcticZymes Technologies ASAAZT.OL · 🇳🇴 Norway
    Same sector: Healthcare (Biotechnology) · Similar size: $207 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $207 M (last known, Jan 5, 2024) · revenue $11 M (year to December 2025)
    65 of 100 (industry or sector 25 + size 28 + country 7 + figures on file 5)
    + Add
  • BioPorto A/SBIOPOR.CO · 🇩🇰 Denmark
    Same sector: Healthcare (Diagnostics and Research) · Similar size: $118 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $118 M (last known, Jan 5, 2024)
    65 of 100 (industry or sector 25 + size 28 + country 7 + figures on file 5)
    + Add
  • Sedana Medical AB (publ)SEDANA.ST · 🇸🇪 Sweden
    Same sector: Healthcare (Medical Instruments) · Similar size: $223 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $223 M (last known, Jan 5, 2024) · revenue $20 M (year to December 2025)
    65 of 100 (industry or sector 25 + size 28 + country 7 + figures on file 5)
    + Add
  • Oriola OyjOKDAV.HE · 🇫🇮 Finland
    Same sector: Healthcare (Retail - Pharmacy) · Similar size: $221 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $221 M (last known, Jan 5, 2024) · revenue $2.1 B (year to December 2025)
    65 of 100 (industry or sector 25 + size 28 + country 7 + figures on file 5)
    + Add
  • OneMedNet CorpONMD · 🇬🇧 UK
    Same sector: Healthcare (Diagnostics and Research) · Similar size: $237 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $237 M (Oct 14, 2026) · revenue $1 M (year to December 2025)
    64 of 100 (industry or sector 25 + size 27 + country 7 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.